Recce Pharmaceuticals Ltd
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RCE.AX research report →
Price Chart
About the company
Recce Pharmaceuticals Ltd operates as a biotechnology enterprise, concentrating on the research, advancement, and market introduction of synthetic anti-infective treatments across Australia, the United States, and the United Kingdom. The company's foremost developmental drug, RECCE 327, is intended to address blood infections and sepsis caused by E. coli and S.
- CEO
- James Hamilton-Bray Graham
- IPO
- 2016
- Employees
- 8
- HQ
- Sydney, NSW, AU
Get TickerSpark's AI analysis on RCE.AX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $111.61M
- P/E
- -3.22
- Fwd P/E
- 3.29
- PEG
- 0.11
- P/S
- 198.40
- P/B
- -5.67
- EV/EBITDA
- -4.54
- Div Yield
- 0.00%
- Gross Margin
- -277.34%
- Op Margin
- -3942.32%
- Net Margin
- -5378.06%
- ROE
- 279.21%
- ROIC
- 290.72%
Latest fiscal year · YoY change
- Revenue
- $7.51M+49.3%
- Gross Profit
- $-2,937,489-34.2%
- Op Income
- $-22,880,440
- Net Income
- $-21,428,089-21.3%
- EPS
- $-0.09+9.3%
- OCF Growth
- -57.1%
- FCF Growth
- -55.6%
- 52W High
- $0.73
- 52W Low
- $0.35
- 50D MA
- $0.40
- 200D MA
- $0.50
- Beta
- 0.39
- RSI (14)
- 42
- Avg Volume
- 178.80K
No earnings-call transcripts are available for RCE.AX yet.
- Free Float
- 43.2%
- Shares Outstanding
- 305.77M
- Float Shares
- 132.00M
Our RCE.AX coverage
Recent articles, reports, and earnings notes.
No research on RCE.AX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate RCE.AX report →Baidu misses Q2 revenue and earnings estimates as core business slips
proactiveinvestors.com · Aug 18
Bank of England holds rates but three dissenters vote for hike
proactiveinvestors.com · Jul 30
Recce Pharmaceuticals positioned for US$66.9 billion US biodefence strategy
proactiveinvestors.com · Jul 30
Recce Pharmaceuticals advances dual Phase 3 programs and MENA licensing strategy in strong June quarter
proactiveinvestors.com · Jul 21
Twilio faces higher bar heading into quarterly earnings, says Jefferies
proactiveinvestors.com · Jul 21
Halliburton tops Q2 earnings estimates as CEO warns of softer oilfield services market
proactiveinvestors.com · Jul 21
Recce Pharmaceuticals extends share purchase plan deadline to July 24
proactiveinvestors.com · Jul 20
Recce patent extends Vietnam protection to 2041 - ICYMI
proactiveinvestors.com · Jul 17
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.